Global Head of Pharmaceutical Corporate Venture Capital, Asahi Kasei Pharma
Dalton Einhorn leads the global corporate venture capital investing activities for Asahi Kasei Pharma (based in Tokyo) and Asahi Kasei Veloxis (based in North Carolina). His investing focus is primarily in areas such as transplant, chronic renal diseases and immunological conditions such as SLE, Lupus Nephritis, Sjogren’s Syndrome and other disorders. Dalton began his career as an investment banker before moving into sales and marketing, new product commercialization and business development roles at Roche, Daiichi-Sankyo and Novo Nordisk. He has been working in the start-up space on both sides for 15 years. As a father of a child with a pediatric disease he is enthusiastic about paying it forward by helping founders and teams get therapies that can help patients to market.